Swiss-based CeQur raises €116.4M to simplify mealtime insulin delivery for people with diabetes: Here’s how

Horw, Switzerland-based CeQur, a medical device company dedicated to simplifying mealtime insulin delivery for individuals, announced that it has secured $120M (approximately €116.4M) in the financing round.  

The company will use the funds for the continued commercial expansion of CeQur Simplicity, the company’s innovative 4-day wearable insulin delivery device.

Additionally, the company will continue to expand its Sales Force and clinical team to ensure that more people with diabetes can benefit from convenient, discreet, and injection-free dosing.

CeQur’s 40,000 sq. ft. cleanroom facility passed all qualifications in Q4 2024 and will start manufacturing a commercial product in 2025.

“We are grateful for the support of our investors as we accelerate our mission to transform diabetes care,” says Brad Paddock, President and CEO of CeQur.

CeQur: Commercialising simple-to-use insulin delivery devices 

Led by Bradley Paddock, CeQur is commercialising advanced, simple-to-use insulin delivery devices that make it easier for people living with diabetes to adhere to therapy and stay in control of their disease.

The company’s product, CeQur Simplicity, is a simple, four-day wearable Insulin Delivery Device for convenient, injection-free bolus dosing.

One CeQur Simplicity patch holds up to 200 units of rapid-acting insulin administered in two-unit increments and replaces, on average, twelve daily mealtime injections over four days.

Clinical research has shown that nearly 90 per cent of patients using CeQur Simplicity reported following their insulin regimen better as compared to multiple daily injections.

Also, the Patch is clinically proven to improve glycemic control, with patients achieving significantly improved A1C and time-in-range (TIR) goals.

According to the company, it has seen growing adoption of its CeQur Simplicity patch with over 6,000 patients currently using the device.

The Swiss company is improving pharmacy access, with over two-thirds of commercially insured patients on the formulary.

CeQur has agreements with Medicare Part D and State Medicaid programs, leading to more than 80 per cent of claims being covered. The average copayment is under $45 per month.